Medicaid Expenditures and Estimated Rebates for Epinephrine Autoinjectors, 2012 to 2016
The epinephrine autoinjector EpiPen received considerable scrutiny in the past year because Mylan, its manufacturer, increased its list price to $609 even though the only ingredient, epinephrine, was discovered over 100 years ago (the delivery system is patented).
Mylan recently announced a $465 million settlement with the Department of Justice (DOJ) to resolve a fraud investigation, 1 alleging that Mylan misclassified EpiPen as a Discussion | Our estimate of $426 million in excess Medicaid spending for epinephrine autoinjector sales covers only 2 formulations and the years 2012 through 2016. Therefore, we believe that the proposed $465 million settlement underestimates the actual cost of Mylan's strategy, pointing to the limits of litigation as a way of recovering taxpayer funds. Other factors that may have affected the proposed settlement amount include supplemental rebate agreements, litigation costs, and uncertainty regarding the government's responsibility. Despite these limitations, a better way to avert such profit-maximizing strategies would be to prevent manufacturers from classifying their own products as generic or branded for Medicaid rebate purposes. 
Out-of-Pocket Spending Among Commercially Insured Patients for Epinephrine Autoinjectors Between 2007 and 2014
In 2007, Mylan obtained the right to EpiPen, the most widely used epinephrine auto-injector for serious allergic reactions. 1, 2 Since then, Mylan has increased the list price for EpiPen from $94 to $609. 2 In part due to patient outcry over rising out-of-pocket spending, Mylan released a $300 generic EpiPen in December 2016. 3 Whether generic EpiPen decreases out-of-pocket spending depends largely on insurers' benefit design. To date, the generosity of EpiPen coverage has not been well characterized. We assessed EpiPen out-of-pocket spending between January 2007 and December 2014 among the commercially insured, a population that accounts for 70% of annual EpiPen prescriptions. We used national drug codes to identify EpiPen prescription fills (including both EpiPen and EpiPen Jr). To assess EpiPen use, we calculated the annual rate of EpiPen prescription fills per EpiPen patient (patients with ≥1 fill during the year). For each EpiPen patient, we added copays, coinsurance, and deductible payments to calculate annual EpiPen outof-pocket spending. We calculated the percentage of EpiPen patients with at least $100 and $250 in annual EpiPen outof-pocket spending, and the percentage of annual EpiPen total spending (out-of-pocket spending plus insurer reimbursement) attributable to out-of-pocket spending. We inflated spending to 2014 US dollars using the Consumer Price Index. 4 Results | Across the study period, the sample included 191.2 million enrollees, of which 51.7% were female and 27.8% were children ages 0 to 18 years.
Between January 2007 and December 2014, the annual rate of EpiPen prescription fills per EpiPen patient increased from 1.18 to 1.20 (+1.6%) (Table) . During the same period, annual EpiPen out-of-pocket spending per EpiPen patient increased from $33.8 to $75.5 (+123.6%). Levels of EpiPen out-of-pocket spending per EpiPen patient were higher for children than adults in all years, and deductible payments accounted for an increasing proportion of EpiPen outof-pocket spending over time (Figure) .
The percentage of EpiPen patients with at least $100 and $250 in annual EpiPen out-of-pocket spending increased from 3.9% to 18.0% (+365.6%) and from 0.1% to 7.4% (+5631.7%), respectively. Annual EpiPen total spending per EpiPen patient increased from $123.9 to $468.7 (+278.4%); the percentage of this spending paid out-of-pocket decreased from 27.3% to 16.1% (−40.9%).
Discussion | Among commercially insured patients who use EpiPen, annual EpiPen out-of-pocket spending more than doubled between 2007 and 2014. Simultaneously, the annual rate of EpiPen prescription fills barely increased, suggesting that the increased financial burden on patients was not Abbreviation: OOP, out-of-pocket. a EpiPen prescriptions were identified using national drug codes 49502050001 and 49502050002 (single pack and two-pack, respectively); EpiPen Jr prescriptions were identified using national drug codes 49502050101 and 49502050102 (single pack and two-pack, respectively). An "EpiPen patient" is defined as an individual with at least one prescription drug claim with one of these national drug codes during the calendar year. Out-of-pocket spending is the sum of co-payments, co-insurance payments, and deductible payments; total spending is the sum of out-of-pocket spending and insurer reimbursement. The data source is the 2007-2014 Truven MarketScan Commercial Claims and Encounters database. All spending estimates are inflation-adjusted to 2014 dollars using the US Bureau of Labor Statistics Consumer Price Index calculator. Analytic sample sizes vary between study years due to changes in the overall number of insured enrollees included in MarketScan. driven by higher use. Though insurers covered a higher share of total EpiPen spending over time, patients were still only partially protected against the dramatic rise in EpiPen prices. Therefore, our results suggest that while the aggressive pricing by Mylan was a main driver of increased EpiPen out-ofpocket spending, coverage policies also played a role.
With the recent release of generic EpiPen and competitors, the price of epinephrine autoinjectors will likely decrease over time. The impact of these price decreases on patient out-of-pocket spending will vary depending on insurance benefit design. For patients subject to pricesensitive cost-sharing mechanisms such as deductibles or coinsurance, out-of-pocket spending could decrease substantially; for patients subject to copayments, out-of-pocket spending may be less impacted.
Our study is limited by is its reliance on a convenience sample of commercial claims. Our findings highlight the need for patients, physicians, and policymakers to advocate for both fair pricing by pharmaceutical manufacturers and adequate insurance coverage of life-saving medications. Squares represent out-of-pocket spending (the sum of copays, deductibles, and coinsurance); circles represent copayments; diamonds represent deductible payments; and triangles represent coinsurance. All spending estimates are inflated to 2014 US dollars using the US Bureau of Labor Statistics Consumer Price Index calculator. 4 Data were retrieved from the 2007-2014 Truven MarketScan Commercial Claims and Encounters database (http://truvenhealth .com/portals/0/assets/PH_11238_0612_TEMP_MarketScan_WP_FINAL.pdf).
